Literature DB >> 20080649

Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity.

Nitya Jain1, Hai Nguyen, Cynthia Chambers, Joonsoo Kang.   

Abstract

Cytotoxic T lymphocyte antigen-4 (CTLA-4) is an inhibitory receptor on T cells essential for maintaining T cell homeostasis and tolerance to self. Mice lacking CTLA-4 develop an early onset, fatal breakdown in T cell tolerance. Whether this autoimmune disease occurs because of the loss of CTLA-4 function in regulatory T cells, conventional T cells, or both is unclear. We show here that lack of CTLA-4 in regulatory T cells leads to aberrant activation and expansion of conventional T cells. However, CTLA-4 expression in conventional T cells prevents aberrantly activated T cells from infiltrating and fatally damaging nonlymphoid tissues. These results demonstrate that CTLA-4 has a dual function in maintaining T cell tolerance: CTLA-4 in regulatory T cells inhibits inappropriate naïve T cell activation and CTLA-4 in conventional T cells prevents the harmful accumulation of self-reactive pathogenic T cells in vital organs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20080649      PMCID: PMC2824392          DOI: 10.1073/pnas.0910341107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  CTLA-4-Mediated inhibition of early events of T cell proliferation.

Authors:  M C Brunner; C A Chambers; F K Chan; J Hanke; A Winoto; J P Allison
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

2.  Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function.

Authors:  Qizhi Tang; Elisa K Boden; Kammi J Henriksen; Helene Bour-Jordan; Mingying Bi; Jeffrey A Bluestone
Journal:  Eur J Immunol       Date:  2004-11       Impact factor: 5.532

3.  CTLA-4 engagement acts as a brake on CD4+ T cell proliferation and cytokine production but is not required for tuning T cell reactivity in adaptive tolerance.

Authors:  Manabu Inobe; Ronald H Schwartz
Journal:  J Immunol       Date:  2004-12-15       Impact factor: 5.422

4.  Reversal of the TCR stop signal by CTLA-4.

Authors:  Helga Schneider; Jos Downey; Andrew Smith; Bernd H Zinselmeyer; Catherine Rush; James M Brewer; Bin Wei; Nancy Hogg; Paul Garside; Christopher E Rudd
Journal:  Science       Date:  2006-08-24       Impact factor: 47.728

5.  Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo.

Authors:  Simon Read; Rebecca Greenwald; Ana Izcue; Nicholas Robinson; Didier Mandelbrot; Loise Francisco; Arlene H Sharpe; Fiona Powrie
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

6.  A function for interleukin 2 in Foxp3-expressing regulatory T cells.

Authors:  Jason D Fontenot; Jeffrey P Rasmussen; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2005-10-16       Impact factor: 25.606

7.  Regulation of CTLA-4 expression during T cell activation.

Authors:  D Perkins; Z Wang; C Donovan; H He; D Mark; G Guan; Y Wang; T Walunas; J Bluestone; J Listman; P W Finn
Journal:  J Immunol       Date:  1996-06-01       Impact factor: 5.422

Review 8.  A molecular perspective of CTLA-4 function.

Authors:  Wendy A Teft; Mark G Kirchhof; Joaquín Madrenas
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

9.  FOXP3 controls regulatory T cell function through cooperation with NFAT.

Authors:  Yongqing Wu; Madhuri Borde; Vigo Heissmeyer; Markus Feuerer; Ariya D Lapan; James C Stroud; Darren L Bates; Liang Guo; Aidong Han; Steven F Ziegler; Diane Mathis; Christophe Benoist; Lin Chen; Anjana Rao
Journal:  Cell       Date:  2006-07-28       Impact factor: 41.582

10.  Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization.

Authors:  Ruka Setoguchi; Shohei Hori; Takeshi Takahashi; Shimon Sakaguchi
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

View more
  88 in total

1.  Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells.

Authors:  Xuguang Tai; François Van Laethem; Leonid Pobezinsky; Terry Guinter; Susan O Sharrow; Anthony Adams; Larry Granger; Michael Kruhlak; Tullia Lindsten; Craig B Thompson; Lionel Feigenbaum; Alfred Singer
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

Review 2.  Immune checkpoints in central nervous system autoimmunity.

Authors:  Nicole Joller; Anneli Peters; Ana C Anderson; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

3.  Fatal autoimmunity in mice reconstituted with human hematopoietic stem cells encoding defective FOXP3.

Authors:  Jeremy A Goettel; Subhabrata Biswas; Willem S Lexmond; Ada Yeste; Laura Passerini; Bonny Patel; Siyoung Yang; Jiusong Sun; Jodie Ouahed; Dror S Shouval; Katelyn J McCann; Bruce H Horwitz; Diane Mathis; Edgar L Milford; Luigi D Notarangelo; Maria-Grazia Roncarolo; Edda Fiebiger; Wayne A Marasco; Rosa Bacchetta; Francisco J Quintana; Sung-Yun Pai; Christoph Klein; Aleixo M Muise; Scott B Snapper
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

4.  Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition.

Authors:  Srimoyee Ghosh; Alexander Taylor; Melissa Chin; Hon-Ren Huang; Andrew R Conery; Jennifer A Mertz; Andres Salmeron; Pranal J Dakle; Deanna Mele; Alexandre Cote; Hari Jayaram; Jeremy W Setser; Florence Poy; Georgia Hatzivassiliou; Denise DeAlmeida-Nagata; Peter Sandy; Charlie Hatton; F Anthony Romero; Eugene Chiang; Thornik Reimer; Terry Crawford; Eneida Pardo; Venita G Watson; Vickie Tsui; Andrea G Cochran; Laura Zawadzke; Jean-Christophe Harmange; James E Audia; Barbara M Bryant; Richard T Cummings; Steven R Magnuson; Jane L Grogan; Steve F Bellon; Brian K Albrecht; Robert J Sims; Jose M Lora
Journal:  J Biol Chem       Date:  2016-04-07       Impact factor: 5.157

5.  Co-inhibitory molecules: Controlling the effectors or controlling the controllers?

Authors:  Govindarajan Thangavelu; Christa Smolarchuk; Colin C Anderson
Journal:  Self Nonself       Date:  2010-02-16

Review 6.  Immunotherapy in malignant melanoma: recent approaches and new perspectives.

Authors:  Hugo Arasanz; Alejandra Lacalle; Maria José Lecumberri; Ángela Fernández de Lascoiti; Idoia Blanco-Luquin; María GatoCañas; Leyre Pérez-Ricarte; Miren Zuazo; Grazyna Kochan; David Escors
Journal:  Melanoma Manag       Date:  2017-03-01

Review 7.  Unmasking the immune recognition of prostate cancer with CTLA4 blockade.

Authors:  Serena S Kwek; Edward Cha; Lawrence Fong
Journal:  Nat Rev Cancer       Date:  2012-03-01       Impact factor: 60.716

Review 8.  Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.

Authors:  Hélène Bour-Jordan; Jonathan H Esensten; Marc Martinez-Llordella; Cristina Penaranda; Melanie Stumpf; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

9.  CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis.

Authors:  Crisol Álvarez-Quiroga; Carlos Abud-Mendoza; Lesly Doníz-Padilla; Amida Juárez-Reyes; Adriana Monsiváis-Urenda; Lourdes Baranda; Roberto González-Amaro
Journal:  J Clin Immunol       Date:  2011-04-13       Impact factor: 8.317

10.  Potential regulatory role of in vitro-expanded Vδ1 T cells from human peripheral blood.

Authors:  Fang Hua; Ning Kang; Yun-An Gao; Lian-Xian Cui; De-Nian Ba; Wei He
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.